Woodmont Investment Counsel’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.32M | Hold |
27,438
| – | – | 0.07% | 125 |
|
|
2026
Q1 | $1.01M | Sell |
27,438
-7,626
| -22% | -$361K | 0.06% | 131 |
|
|
2025
Q4 | $1.78M | Sell |
35,064
-1,459
| -4% | -$74.6K | 0.11% | 106 |
|
|
2025
Q3 | $2.03M | Sell |
36,523
-1,066
| -3% | -$62.4K | 0.13% | 98 |
|
|
2025
Q2 | $2.59M | Sell |
37,589
-80,833
| -68% | -$5.5M | 0.17% | 90 |
|
|
2025
Q1 | $8.22M | Buy |
118,422
+7,871
| +7% | +$650K | 0.59% | 38 |
|
|
2024
Q4 | $9.51M | Buy |
110,551
+81,163
| +276% | +$8.78M | 0.7% | 32 |
|
|
2024
Q3 | $3.5M | Hold |
29,388
| – | – | 0.26% | 70 |
|
|
2024
Q2 | $4.19M | Buy |
29,388
+1,148
| +4% | +$152K | 0.34% | 61 |
|
|
2024
Q1 | $3.63M | Buy |
28,240
+300
| +1% | +$35.7K | 0.31% | 64 |
|
|
2023
Q4 | $2.89M | Buy |
27,940
+632
| +2% | +$62.5K | 0.27% | 73 |
|
|
2023
Q3 | $2.48M | Hold |
27,308
| – | – | 0.26% | 78 |
|
|
2023
Q2 | $2.21M | Sell |
27,308
-938
| -3% | -$76.6K | 0.23% | 83 |
|
|
2023
Q1 | $2.25M | Buy |
28,246
+1,000
| +4% | +$70.9K | 0.24% | 87 |
|
|
2022
Q4 | $1.84M | Hold |
27,246
| – | – | 0.21% | 95 |
|
|
2022
Q3 | $1.36M | Buy |
27,246
+480
| +2% | +$25.7K | 0.17% | 106 |
|
|
2022
Q2 | $1.49M | Hold |
26,766
| – | – | 0.18% | 102 |
|
|
2022
Q1 | $1.49M | Hold |
26,766
| – | – | 0.17% | 107 |
|
|
2021
Q4 | $1.5M | Sell |
26,766
-26
| -0.1% | -$1.41K | 0.19% | 98 |
|
|
2021
Q3 | $1.29M | Hold |
26,792
| – | – | 0.19% | 97 |
|
|
2021
Q2 | $1.12M | Buy |
26,792
+26
| +0.1% | +$1.01K | 0.18% | 102 |
|
|
2021
Q1 | $902K | Hold |
26,766
| – | – | 0.15% | 106 |
|
|
2020
Q4 | $935K | Sell |
26,766
-12,968
| -33% | -$448K | 0.17% | 97 |
|
|
2020
Q3 | $1.38M | Hold |
39,734
| – | – | 0.3% | 74 |
|
|
2020
Q2 | $1.3M | Hold |
39,734
| – | – | 0.31% | 73 |
|
|
2020
Q1 | $1.2M | Hold |
39,734
| – | – | 0.33% | 73 |
|
|
2019
Q4 | $1.15M | Hold |
39,734
| – | – | 0.26% | 88 |
|
|
2019
Q3 | $1.03M | Hold |
39,734
| – | – | 0.25% | 91 |
|
|
2019
Q2 | $1.01M | Hold |
39,734
| – | – | 0.25% | 91 |
|
|
2019
Q1 | $1.04M | Hold |
39,734
| – | – | 0.27% | 86 |
|
|
2018
Q4 | $915K | Buy |
+39,734
| New | +$883K | 0.26% | 90 |
|
|
2018
Q3 | – | Sell |
-41,314
| Closed | -$953K | – | 169 |
|
|
2018
Q2 | $953K | Buy |
+41,314
| New | +$982K | 0.26% | 92 |
|
|
2018
Q1 | – | Sell |
-41,314
| Closed | -$1.11M | – | 184 |
|
|
2017
Q4 | $1.11M | Sell |
41,314
-1,180
| -3% | -$30K | 0.29% | 88 |
|
|
2017
Q3 | $1.02M | Buy |
+42,494
| New | +$960K | 0.28% | 90 |
|
Other funds holding NVO
EHC
SRIM
MG
OAM
Woodmont Investment Counsel's NVO Position: Q2 2026 in Review
Woodmont Investment Counsel held its Novo Nordisk (NVO) position steady in Q2 2026 at 27,438 shares worth $1.32M. The position accounts for 0.07% of the portfolio, ranked #125.
Woodmont Investment Counsel first reported a position in NVO in Q3 2017 and has held it in 34 quarters since. The position peaked at $9.51M in Q4 2024. 819 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Woodmont Investment Counsel held 27,438 shares of Novo Nordisk worth $1.32M as of Q2 2026.
- Woodmont Investment Counsel left its Novo Nordisk share count unchanged in Q2 2026.
- Novo Nordisk made up 0.07% of Woodmont Investment Counsel's portfolio in Q2 2026, its #125 holding.
- Woodmont Investment Counsel first reported a position in Novo Nordisk in Q3 2017 and has held it in 34 quarters since.
- Woodmont Investment Counsel's Novo Nordisk position peaked at $9.51M in Q4 2024.
- 819 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Woodmont Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.